Company Research Report: Kriba

Company Overview

Name: Kriba

Mission

Kriba aims to impact healthcare globally by accelerating non-invasive screening, diagnosis, and monitoring of infections in serous fluids with fast, empathetic, accessible, relevant, efficient, and cost-effective solutions.

Founded By

Founder: Javier Jimenez

Key People

Javier Jimenez - Founder, CEO

Rita Quesada - Chief Quality and Regulatory Compliance Officer

Belen Lopez - CFO & Chief Human Resources Officer

Beatrice Jobst - Chief Data Officer

Fabiao Santos - R&D Laboratory Director

Manuel Navarrete - R&D Software Engineering Director

Headquarters

Barcelona Science Park, Spain

Number of Employees

No information is available

Revenue

No information is available

Company Recognition

Kriba is recognized for its innovative non-invasive white blood cell counter for serous fluid infections, offering a unique, easy, and cost-effective diagnosis method.

Products

Neosonics®

Description

Neosonics® is a first-in-class medical device that enables non-invasive counting of white blood cells in serous fluids, aiding in the fast, easy, and cost-effective screening, diagnosis, and monitoring of infections.

Key Features

High-resolution ultrasound

Unique coupling materials

Deep learning AI algorithms

Areas of Care

Newborn: Screening and monitoring for meningitis in newborns and infants.

Kidney: Cell-level determination in peritoneal dialysis drainage bags.

Eye Care: Early detection and monitoring of uveitis.

Recent Developments

Events and Exhibitions

MICCAI 2024: Selected for oral presentations, highlighting deep learning-based non-invasive meningitis screening with global collaboration.

ASN Kidney Week 2024: Debut as an exhibitor focusing on Neosonics® for PD-related peritonitis. Demonstrated technology for detecting peritonitis infections.

ISPD Dubai 2024: Participated in this global event for peritoneal dialysis; showcased Neosonics®’ capabilities in early detection of peritonitis.

Clinical Developments

Neosonics® Clinical Trials: Conducted multicenter clinical studies across Spain, Mozambique, and Morocco for meningitis screening in infants.

Strategic Partnerships

Kriba collaborates with renowned experts, hospitals, and global health organizations to ensure the development of devices catering to both high and low-income settings.

Summary

Kriba, headquartered in the Barcelona Science Park, is led by CEO Javier Jimenez and aims to revolutionize healthcare through R&D and non-invasive medical devices to monitor infections in serous fluids. It is highly recognized for its innovative products like Neosonics®, targeting critical healthcare needs like meningitis, peritonitis, and uveitis. Recently, Kriba's involvement in global conferences and its clinical trial results underscore its influential role in advancing healthcare technology and accessibility worldwide.